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Abstract
Introduction:  Vestibular  migraine  (VM)  is  now  accepted  as  a  common  cause  of  episodic  ver-
tigo. Treatment  of  VM  involves  two  situations:  the  vestibular  symptom  attacks  and  the  period
between attacks.  For  the  latter,  some  prophylaxis  methods  can  be  used.  The  current  recom-
mendation  is  to  use  the  same  prophylactic  drugs  used  for  migraines,  including  -blockers,
antidepressants  and  anticonvulsants.  The  recent  diagnostic  deﬁnition  of  vestibular  migraine
makes the  number  of  studies  on  its  treatment  scarce.
Objective:  To  evaluate  the  efﬁcacy  of  prophylactic  treatment  used  in  patients  from  a  VM
outpatient  clinic.
Methods:  Review  of  medical  records  from  patients  with  VM  according  to  the  criteria  of  the
Bárány Society/International  Headache  Society  of  2012  criteria.  The  drugs  used  in  the  treat-
ment and  treatment  response  obtained  through  the  visual  analog  scale  (VAS)  for  dizziness
and headache  were  assessed.  The  pre  and  post-treatment  VAS  scores  were  compared  (the
improvement  was  evaluated  together  and  individually,  per  drug  used).  Associations  with  clinical
subgroups  of  patients  were  also  assessed.
Results:  Of  the  88  assessed  records,  47  were  eligible.  We  included  patients  that  met  the
diagnostic  criteria  for  VM  and  excluded  those  whose  medical  records  were  illegible  and
those of  patients  with  other  disorders  causing  dizziness  and/or  headache  that  did  not
meet the  2012  criteria  for  VM.  80.9%  of  the  patients  showed  improvement  with  prophylaxis
(p <  0.001).  Amitriptyline,  Flunarizine,  Propranolol  and  Topiramate  improved  vestibular  symp-
toms (p  <  0.001)  and  headache  (p  <  0.015).  The  four  drugs  were  effective  in  a  statistically
signiﬁcant  manner.  There  was  a  positive  statistical  association  between  the  time  of  vestibular
symptoms  and  clinical  improvement.  There  was  no  additional  beneﬁt  in  hypertensive  patients
who used  antihypertensive  drugs  as  prophylaxis  or  depressed  patients  who  used  antidepressants
in relation  to  other  prophylactic  drugs.  Drug  association  did  not  show  statistically  signiﬁcant
results in  relation  to  the  use  of  a  single  drug. Please cite this article as: Salmito MC, Duarte JA, Morganti LOG, Brandão PVC, Nakao BH, Villa TR, et al. Prophylactic treatment of
vestibular migraine. Braz J Otorhinolaryngol. 2016. http://dx.doi.org/10.1016/j.bjorl.2016.04.022
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Conclusions:  Prophylactic  medications  used  to  treat  VM  improve  the  symptoms  of  this  disease,
but there  is  no  statistically  signiﬁcant  difference  between  the  responses  of  prophylactic  drugs.
The time  of  vestibular  symptom  seems  to  increase  the  beneﬁt  with  prophylactic  treatment.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
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Tratamento  proﬁlático  da  migrânea  vestibular
Resumo
Introduc¸ão: A Migrânea  Vestibular  (MV)  é  aceita  atualmente  como  uma  causa  comum  de  ver-
tigem episódica.  O  tratamento  da  MV  envolve  duas  situac¸ões:  as  crises  de  sintomas  vestibulares
e o  período  intercrise.  Para  este  último,  pode-se  utilizar  algum  método  de  proﬁlaxia.  A
recomendac¸ão atual  é  que  se  utilizem  os  mesmos  medicamentos  proﬁláticos  utilizados  para
a enxaqueca,  o  que  inclui  os  -bloqueadores,  antidepressivos  e  anticonvulsivantes.  A  recente
deﬁnic¸ão diagnóstica  da  migrânea  vestibular  torna  escasso  o  número  de  estudos  sobre  seu
tratamento.
Objetivo: Avaliar  a  eﬁcácia  do  tratamento  proﬁlático  utilizado  em  pacientes  em  um  ambulatório
de MV.
Método:  Revisão  de  prontuários  de  pacientes  com  MV  pelos  critérios  da  Bárány  Soci-
ety/International  Headeache  Society  de  2012.  Foram  pesquisados  os  medicamentos  utilizados  e
resposta ao  tratamento  obtida  através  da  Escala  Visual-Analógica  (EVA)  para  tontura  e  cefaleia.
Foram comparados  os  escores  da  EVA  pré  e  pós-tratamento  (a  melhora  foi  avaliada  em  conjunto
e individualmente  por  droga  utilizada).  Também  foram  pesquisadas  relac¸ões  com  subgrupos
clínicos dos  pacientes.
Resultados:  De  88  prontuários  estudados,  47  foram  elegíveis.  Incluiu-se  os  pacientes  que
preenchiam  os  critérios  diagnósticos  para  MV,  foram  excluídos  os  prontuários  ilegíveis  e  aque-
les de  pacientes  com  outro  distúrbio  causador  de  tontura  e/ou  cefaleia  que  não  preenchiam
critérios  de  2012  para  MV.  Apresentaram  melhora  com  a  proﬁlaxia  80,9%  dos  pacientes
(p <  0,001).  Amitriptilina,  ﬂunarizina,  propranolol  e  topiramato  apresentaram  melhora  para
sintomas  vestibulares  (p  <  0,001)  e  para  cefaleia  (p  <  0,015).  Os  quatro  medicamentos  foram
eﬁcazes de  forma  estatisticamente  signiﬁcante.  Houve  relac¸ão  estatística  positiva  entre  tempo
de sintoma  vestibular  e  melhora  clínica.  Não  houve  benefício  adicional  para  hipertensos  que
utilizaram  anti-hipertensivos  como  proﬁlaxia  ou  para  os  deprimidos  que  usaram  antidepres-
sivos em  relac¸ão  ao  uso  dos  outros  proﬁláticos.  A  associac¸ão  de  medicamentos  não  mostrou
resultados  estatisticamente  signiﬁcantes  do  uso  de  um  medicamento  isolado.
Conclusões:  Os  medicamentos  proﬁláticos  utilizados  para  MV  melhoram  os  sintomas  dessa
doenc¸a, porém  não  há  diferenc¸a  estatisticamente  signiﬁcante  entre  as  respostas  dos  medica-
mentos proﬁláticos.  O  tempo  de  sintoma  vestibular  parece  aumentar  melhora  obtida  com  o
tratamento  proﬁlático.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
I
D
c
d
a
t
t
t
v
s
a
v
a
t
I
s
p
h
entroduction
izziness  is  one  of  the  most  common  symptoms  in  medi-
al  practice,  with  an  incidence  of  up  to  30%  a  year  and,
espite  its  difﬁcult  approach,  it  is  usually  possible  to  reach
 diagnosis.1,2 Vestibular  disorders  are  the  main  diseases
hat  manifest  with  dizziness  complaints  and,  among  them,
he  most  common  are  Benign  Paroxysmal  Positional  Ver-
igo  (BPPV),  Vestibular  Migraine  (VM),  Meniere’s  disease  and
estibular  neuritis,  in  decreasing  order  of  frequency.2
Migraine  is  a  multifactorial  chronic  disease.  Its  main
ymptom  is  headache,  typically  unilateral,  pulsatile,
B
e
nssociated  with  photophobia  and  phonophobia,  nausea  and
omiting.3,4 The  association  between  migraine  headache
nd  vertigo  has  been  known  for  a  long  time  and  occurs
hree  times  more  often  than  if  it  would  by  chance  alone.5
n  1984,  Kayan  and  Hood  carried  out  a  large  study  that
howed  a  higher  prevalence  of  otoneurological  symptoms  in
atients  with  migraine,  compared  to  patients  with  tension
eadache.6 Vestibular  migraine  as  a  speciﬁc  entity,  how-
ver,  was  only  recently  described  in  1999  by  Dieterich  and
randt,7 and  is  characterized  by  the  association  of  vertigo
pisodes  and  migraine  headache.  To  date,  its  deﬁnition  is
ot  uniform  among  the  authors.  Diagnostic  criteria  were
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Prophylactic  treatment  of  vestibular  migraine  
proposed  by  Neuhauser  in  20018 and  revised  in  2012  by
the  Bárány  Society  and  the  International  Headache  Soci-
ety  (IHS),9 and  was  included  in  the  third  version  of  the
International  Classiﬁcation  of  Headache  Disorders  --  ICHD.10
The  VM  is  now  accepted  as  a  frequent  cause  of  episodic
vertigo.
Treatment  of  VM  involves  two  situations:  treatment  of
attacks  and  prophylactic  treatment.  For  the  latter,  some
type  of  prophylaxis  can  be  used.11,12 The  current  recom-
mendation  is  to  use  the  same  prophylactic  drugs  for  VM  as
for  migraine,  which  include  -blockers,  antidepressants  and
anticonvulsants.11--13
The  aim  of  this  study  was  to  evaluate  the  improvement
in  VM  symptoms  (headache  and  vestibular  symptoms)  after
drug  prophylaxis  in  patients  with  VM,  treated  at  a  VM  clinic
belonging  to  the  Discipline  of  Otoneurology.
Methods
An  observational,  longitudinal,  retrospective  study  of  medi-
cal  record  review  was  carried  out.  We  evaluated  the  records
of  all  patients  treated  at  the  Vestibular  Migraine  Outpa-
tient  Clinic  of  the  Discipline  of  Otology  and  Neurotology,
Department  of  Otolaryngology  and  Head  and  Neck  Surgery
of  the  Universidade  Federal  de  São  Paulo  since  its  creation  in
February  2011  until  June  2013.  This  study  was  approved  by
the  Research  Ethics  Committee  of  the  Universidade  Federal
de  São  Paulo  (code  19615313.13.5.0000.5505).
The  diagnostic  criteria  for  vestibular  migraine  used  were
the  criteria  proposed  in  2012  by  the  Bárány  Society  and
the  International  Headache  Society  (IHD),9 included  in  the
third  version  of  the  International  Classiﬁcation  of  Headache
Disorders  --  ICHD.10 It  included  patients  with  ‘‘vestibular
migraine’’  and  ‘‘probable  vestibular  migraine.’’  As  the
Vestibular  Migraine  Outpatient  Clinic  of  this  Universidade
Federal  de  São  Paulo  was  created  in  2011,  information  from
medical  records  was  individually  reviewed  and  patients  who
met  the  2001  criteria  for  VM,  but  not  the  new  2012  crite-
ria,  or  those  showing  dubious  information  about  it,  were
excluded.
Due  to  the  wide  variation  in  the  literature  regarding
the  terms  used  in  otoneurology  (dizziness,  vertigo,  etc.),
in  this  article  we  decided  to  use  the  terms  proposed  for
the  ‘‘Classiﬁcation  of  Vestibular  Symptoms’’,  by  the  Bárány
Society  in  2009.14
Although  it  is  an  ambulatory  care  clinic,  the  vestibular
migraine  outpatient  clinic  was  created  in  order  to  better
understand  this  disease,  which,  even  though  having  been
described  only  in  1999,  is  currently  the  second  most  frequent
diagnosis  of  vestibular  diseases.  The  patients  treated  at  the
clinic  are  those  who  met  the  diagnostic  criteria  and  were
referred  from  the  otoneurology  clinic.  Each  clinic  patient
had  a  standardized  questionnaire  completed  by  the  exam-
iner  at  each  visit.  Among  other  things,  the  outpatient  clinic
patients  are  asked  to  answer  two  questions  at  every  consul-
tation:  ‘‘Have  you  improved  with  treatment?’’  and  ‘‘Give  a
score  from  0  to  10  for  your  symptoms,  where  0  is  the  min-
imum,  or  best  possible  and  10  is  the  maximum,  or  worst
possible.’’  At  each  consultation,  patients  are  treated  dur-
ing  the  normal  routine  of  the  clinic,  by  residents  or  fellows
of  otoneurology,  supervised  by  a  single  advisor.
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We  included  all  records  of  patients  with  vestibular
igraine  and  the  following  information  was  considered:
 Epidemiological  data:  name,  gender,  age,  profession  and
place  of  birth.
 Clinical  characteristics  of  the  disease.
 Past  medical  history.
 Results  of  the  treatments  evaluated  through  the  generic
question  ‘‘Have  you  improved  with  treatment?’’  and
through  the  Visual  Analog  Scale  (VAS).
Files  of  patients  with  another  disorder  causing  dizziness
nd/or  headache,  those  who  did  not  meet  the  2012  criteria
or  VM  and  those  with  illegible  records  or  with  incomplete
r  conﬂicting  information  were  excluded.
Each  patient  was  evaluated  through  the  VAS  for  the  30
ays  prior  to  prophylactic  treatment  and  VAS  for  three
onths  after  the  beginning  of  prophylactic  treatment
ith  different  drugs.  The  VAS  was  applied  to  the  symp-
om  headache  and  Vestibular  Symptoms  (VS).  Vestibular
ymptoms  varied  somewhat  among  patients.  Some  had  spon-
aneous  vertigo,  others  positional  vertigo,  while  others  had
estibular-visual  symptoms.  Due  to  this  variation,  these
ymptoms  were  grouped  as  VS.
Clinical  improvement  was  determined  by  the  difference
etween  these  scores,  called  therapeutic  response.  In  case
f  need  for  treatment  change  due  to  drug  failure  or  side
ffects,  or  for  ﬁnancial  reasons,  the  initial  drug  was  changed
o  a  second  medication.  At  the  VM  outpatient  clinic,  the
hoice  of  drugs  is  based  on  the  patient’s  proﬁle  and  choice,
or  example,  antidepressants  for  those  with  anxiety  and
ntihypertensive  agents  for  those  with  associated  hyperten-
ion.
The  period  of  three  months  between  the  interventions
deﬁnition  of  improvement/failure)  was  determined  based
n  the  fact  that  the  therapeutic  effect  of  drugs  only  begins
fter  2--4  weeks  and  the  fact  that  the  disease  has  natural
eriods  of  improvement  and  worsening  and  that  patients,  in
 given  month,  can  have  more  or  fewer  crises  due  to  natural
pisodic  nature  of  the  disease  and  not  due  to  real  improve-
ent/worsening.  All  patients  receive  the  same  advice  on
he  beneﬁts  of  eating  habits,  sleep  hygiene,  physical  activ-
ty  practice  and  identiﬁcation  and  interruption  of  migraine
riggers.
Pre-  and  post-treatment  gain  values  were  compared  using
he  Kruskal--Wallis  test.  Other  statistical  tests  used  were
he  equal  proportions  test  and  Spearman’s  correlation  test.
ifferences  were  considered  statistically  signiﬁcant  when
 <  0.05  for  a  95%  conﬁdence  interval.
esults
pidemiological  results
fter  the  analysis  of  88  medical  records  of  patients  diag-
osed  with  VM,  47  were  maintained  according  to  the
nclusion  and  exclusion  criteria.  The  study  group  had  a
ean  age  of  45.9  years  (range  19--69  years)  and  mean
uration  of  symptoms  of  10.8  years  for  headache  and  6.0
ears  for  Vestibular  Symptoms  (VS).  Due  to  the  retrospec-
ive  nature  of  the  study,  some  data  were  not  identiﬁed  in
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Table  1  Age  and  duration  of  symptoms  (years)  in  patients
with VM.
Age  Time  headache  Time  of  VS
Mean  45.9  10.8  6.0
Median 47.5  7.0  4.0
Deviation  10.9  11.0  6.5
Minimum  19  1.0  0.3
Maximum  69  50  30
n 46  46  47
VM, vestibular migraine; VS, vestibular symptoms.
Table  2  Comorbidities  in  patients  with  VM.
Disease  n  %
None  15  31.9
SAH 15  31.9
DM 2  4.3
Dyslipidemia  9  19.1
Epilepsy  2  4.3
Hypothyroidism  6  12.8
Anxiety/depression  8  17.0
Others 14  29.8
VM, vestibular migraine; SAH, systemic arterial hypertension;
DM, diabetes mellitus.
Table  3  Clinical  improvement  in  patients  with  VM.
Improved?  Yes  p
n  %
Amitriptyline  25  10  76.9%  0.006
Amitriptyline  50  2  100%  0.046
Flunarizine  10  10  90.9%  <0.001
Nortriptyline  50  1  100% *
Propranolol  40 2  66.7%  0.083
Propranolol  80 4  100%  0.005
Topiramate  100 4  57.1%  0.094
Topiramate  200 1  100% *
Valproate  1000  1  100% *
Valproate  500  2  66.7%  0.083
Venlafaxine  75 1  100% *
Overall  38  80.9%  <0.001
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Table  4  Values  obtained  with  the  visual  analog  scale
for headaches,  before  and  after  use  of  prophylactic  drug,
according  to  the  drug  used  in  patients  with  VM.
Prophylaxis  Headache  pre  Headache  post  p
Mean  n  Mean  n
Amitriptyline  25  7.54  13  2.82  11  <0.001
Amitriptyline  50  6.00  2  4.00  2  0.317
Flunarizine  10  7.73  11  3.22  9  0.002
Nortriptyline  50  8.00  1  3.00  1  0.317
Propranolol  40 6.00 3  3.00  3  0.178
Propranolol  80 8.75 4  4.00 4  0.015
Topiramate  100 8.71 7  4.33 6  0.002
Topiramate  200  10.00  1  8.00  1  0.317
Valproate  1000  7.00  1  0.00  1  0.317
Valproate  500  9.00  2  3.00  2  0.121
Venlafaxine  75 10.00  1  0.00  1  0.317
Overall  7.87  46  3.32  41  <0.001
VM, vestibular migraine.
Table  5  Values  obtained  with  the  visual  analog  scale  for
vestibular  symptoms,  before  and  after  use  of  prophylactic
drug, according  to  the  drug  used  in  patients  with  VM.
Prophylaxis  VS  pre  VS  post  p
Mean  n  Mean  n
Amitriptyline  25  6.38  13  2.55  11  0.001
Amitriptyline  50  6.50  2  2.50  2  0.221
Flunarizine  10  6.82  11  4.56  9  0.050
Nortriptyline  50  8.00  1  2.00  1  0.317
Propranolol  40  6.33  3  4.00  3  0.197
Propranolol  80  7.75  4  3.25  4  0.034
Topiramate  100  8.29  7  3.33  6  0.006
Topiramate  200 7.00  1  0.00  1  0.317
Valproate  1000 5.00 1  0.00  1  0.317
Valproate  500 7.50  2  2.00  2  0.121
Venlafaxine  75 10.00 1  0.00  1  0.317
Overall  7.04  46  3.05  41  <0.001
VM, vestibular migraine; VS, vestibular symptoms.
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l* p not calculated due to small n.
VM, vestibular migraine.
he  patients’  records  and  could  not  be  obtained  by  phone
ontact.  Because  of  this,  some  data  appear  with  a  different
umber  from  the  original  47  (Table  1).  There  was  a  predom-
nance  of  women  (93.6%).  Nearly  a  third  of  patients  did  not
ave  any  comorbidity  and,  among  those  with  comorbidities,
ypertension  was  the  most  prevalent  one  (Table  2).
eneﬁts  of  drug  prophylaxis
ost  of  the  patients  (80.9%)  reported  improvement  with  the
se  of  different  prophylactic  drugs  (Table  3),  with  a  statis-
ically  signiﬁcant  difference  (p  <  0.001)  when  compared  to
hose  who  said  they  had  not  improved.
o
t
(When  quantitatively  evaluating  the  VAS  values  for
eadache  and  vestibular  symptoms,  these  were  lower  in
he  post-treatment  period,  conﬁrming  the  qualitative  ﬁnd-
ng  that  there  was  clinical  improvement  (Tables  4  and  5).
ll  patients  showed  improvement  for  both  symptoms  with  a
tatistically  signiﬁcant  difference  (p  <  0.001).
How  much  each  prophylactic  medication  improved
atients’  symptoms,  calculated  as  the  difference  between
re-  and  post-treatment  VAS  (treatment  response),  also
howed  improvement  (Table  6).  When  comparing  each  value
f  therapeutic  response  obtained  with  each  type  of  prophy-
axis  used,  excluding  the  cases  of  drugs  used  in  only  one
r  two  individuals,  it  was  observed  that  there  was  no  sta-
istically  signiﬁcant  difference  among  different  medications
Table  7).
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Table  6  Therapeutic  response  assessed  by  the  mean  vari-
ation of  VAS  after  prophylactic  treatment  in  patients  with
VM.
Prophylaxis  Headache  VS
Mean  n  Mean  n
Amitriptyline  25  −4.82  11  −4.00  11
Amitriptyline  50  −2.00  2  −4.00  2
Flunarizine  10  −4.33  9  −2.56  9
Nortriptyline  50 −5.00 1  −6.00  1
Propranolol  40 −3.00 3  −2.33 3
Propranolol  80 −4.75 4  −4.50 4
Topiramate  100 −4.50 6  −5.00 6
Topiramate  200  −2.00  1  −7.00  1
Valproate  1000  −7.00  1  −5.00  1
valproate  500 −6.00  1  −6.00  1
Venlafaxine  75 −10.00 1  −10.00  1
Overall −4.53 40  −4.10  40
VAS, visual analog scale; VM, vestibular migraine; VS, vestibular
symptoms.
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Table  7  Therapeutic  response  appraised  by  the  mean  variation  
drug used.
Prophylaxis  Headache  
Mean  n  p  
Amitriptyline  25 −4.82 11 0.97
Flunarizine 10 −4.33 9  
Propranolol  40  −3.00  3  
Propranolol 80  −4.75  4  
Topiramate  100  −4.50  6  
Overall −4.53  40  
VM, vestibular migraine; VS, vestibular symptoms.
Table  8  Statistical  correlation  between  the  response  to  therapy  
VM and  time  of  symptoms  (migraine  and  VS).
Prophylaxis  Time  of
Correl.  (r)  
Amitriptyline  25 Pain  −10.4%  
SV 11.5%  
Flunarizine 10 Pain  47.0%  
SV −61.4%  
Propranolol 40 Pain  50.0%  
SV 0.0%  
Propranolol 80 Pain  100.0%  
SV −100.0%  
Topiramate  100 Pain 77.0%  
SV 35.3%  
Overall Pain 23.5%  
VS 14.8%  
VAS, visual analog scale; VM, vestibular migraine; VS, vestibular sympt PRESS
5
tatistical  correlations  for  treatment  strategies
e  sought  to  assess  whether  there  was  an  association
etween  how  much  the  patient  improved  (treatment
esponse)  and  duration  of  symptoms,  using  Spearman’s
orrelation  test.  There  was  no  statistically  signiﬁcant  asso-
iation  with  any  group  of  drugs,  but  regarding  the  overall
roup,  there  was  a  directly  proportional  and  statistically
igniﬁcant  association  (p  =  0.037)  between  duration  of  dizzi-
ess  reported  by  the  patient  and  the  observed  therapeutic
esponse  for  the  VS,  as  shown  in  Table  8.
The  group  of  hypertensive  patients  using  -blockers  as
rophylactic  treatment  for  vestibular  migraine  and  the
roup  of  anxious/depressed  patients  that  used  antidepres-
ants,  however,  showed  no  statistically  signiﬁcant  advantage
hen  using  these  drug  groups  when  compared  to  those  using
ther  drugs  (Tables  9  and  10).
There  was  no  statistically  signiﬁcant  difference  among
reatment  responses  obtained  with  the  three  different
reatment  regimens  used:  one  drug,  one  medication  after
ubstitution  due  to  treatment  failure  or  the  combination  of
wo  drugs  (Table  11).
of  VAS  after  prophylactic  treatment  in  patients  with  VM  per
VS
Mean  n  p
7 −4.00  11 0.608
−2.56 9
−2.33  3
−4.50  4
−5.00  6
−4.10  40
assessed  by  VAS  after  prophylactic  treatment  in  patients  with
 headache  Time  of  VS
p  Correl.  (r)  p
0.761  −12.3%  0.719
0.735  48.4%  0.132
0.202  45.3%  0.221
0.079  9.3%  0.812
0.667  100.0%  --
1.000  86.6%  0.333
--  100.0%  --
--  33.3%  0.667
0.073  77.0%  0.073
0.493  35.3%  0.493
0.150  30.4%  0.056
0.368  33.1%  0.037
oms.
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Table  9  Comparison  between  therapeutic  response  mea-
sured by  VAS  variation  in  hypertensive  patients  receiving
-blocker  drug  prophylaxis  and  hypertensive  patients  receiv-
ing other  drugs.
Drug  Response  for  pain  Response  for  VS
Others  Propranolol  40  Others  Propranolol  40
Mean  −4.20 −3.50  −4.60  −3.50
n 10  2  10  2
p 0.914  0.746
VAS, visual analog scale; VS, vestibular symptoms.
Table  10  Comparison  of  therapeutic  response  at  VAS  for
anxious individuals  treated  with  antidepressant  prophylaxis
and VAS  for  anxious  individuals  treated  with  other  drugs.
Anxiety  Response  for  pain  Response  for  VS
Others  Antidepressants  Others  Antidepressants
Mean  −3.67  −10.00  −4.17  −5.00
n 6  1  6  1
p 0.094  1.000
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different  drugs  used  (Table  7). This  can  be  seen  as  a  posi-VAS, visual analog scale; VS, vestibular symptoms.
iscussion
estibular  migraine  shows  a  predominance  of  female
atients,  with  a  ratio  of  1.5--5:1,  occurring  at  any  age  and
he  headache  usually  precedes  vestibular  symptoms  in  most
atients.7,15 The  same  was  observed  in  this  sample  with.
3.6%  of  women,  mean  age  of  45.9  years  and  mean  dura-
ion  of  headache  longer  than  the  mean  time  of  vestibular
ymptoms  (Table  1).
The  beneﬁt  of  drug  prophylaxis  for  VM  is  still  a  vast  ﬁeld
f  study.  Overall,  it  is  accepted  that  the  prophylactic  treat-
ent  for  VM  is  effective,  but  there  are  no  double-blind
andomized  trials  comparing  different  treatments.12,13 Due
o  the  recent  description  of  VM,  only  studies  on  migraine
ssociated  with  dizziness  or  imbalance  were  found  in  the  lit-
rature.  Reploeg  and  Goebel  reported  72%  of  patients  with
ertigo  and  imbalance  symptoms  improved  after  prophylac-
ic  treatment.16 Similar  results  were  observed  in  this  study,
n  which  80.9%  of  patients  reported  some  improvement  with
he  use  of  different  prophylactic  drugs  (Table  3).
t
p
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Table  11  Comparison  of  the  therapeutic  responses  measured  by  
a substitute  medication  after  the  failure  of  the  ﬁrst  one  and  assoc
Regimen  
Therapeutic
response  for
headache
One  medication  
A substitute  medication  
Association  of  two  medications  
Therapeutic
response for  VS
One  medication  
A substitute  medication  
Association  of  two  medications  
VAS, visual analog scale; VS, vestibular symptoms. PRESS
Salmito  MC  et  al.
No  studies  were  found  comparing  groups  of  prophylactic
rugs  in  patients  with  diagnostic  criteria  for  VM.  Even  review
rticles  on  this  topic  failed  to  reach  conclusions  about  the
est  drug  choice  for  prophylaxis.12,13,17
The  therapeutic  response  to  episodic  disorders,  such  as
eniere’s  disease  or  vestibular  migraine  is  more  difﬁcult  to
tudy  due  to  natural  disease  ﬂuctuations.  Disease  improve-
ent  after  one  month,  for  instance,  may  be  due  to  a  natural
symptomatic  period,  rather  than  due  to  a  therapeutic
ffect  of  an  intervention.  The  longer  the  period  of  evalu-
tion  of  therapeutic  response,  the  more  reliable  it  will  be.
he  3-month  period  used  in  this  study  was  empirically  cho-
en,  respecting  the  minimum  of  2--4  weeks  for  drug  action
nset  and  adding  2  more  months.  Duration  longer  than  the
-month  period  could  lead  to  lower  adherence  to  treatment
y  patients.
This  study  also  showed  quantitative  beneﬁts  with  drug
reatment  for  VM  prophylaxis,  when  using  the  VAS.  Despite
he  imperfections  of  this  assessment  method,  some  things
ay  be  postulated.  There  was  a statistically  signiﬁcant
mprovement  in  headache  and  VS,  but  some  drugs  alone
howed  improvement  with  no  signiﬁcant  difference.  Daily
oses  of  25  mg  of  amitriptyline;  10  mg  of  ﬂunarizine;  80  mg
f  propranolol  and  100  mg  of  topiramate  showed  symptom
mprovement  with  statistically  signiﬁcant  difference.  It  is
oteworthy  that  this  occurred  also  for  both  the  symptom
f  headache  and  for  the  VS,  and,  likewise,  the  drugs  that
howed  no  statistical  difference  for  vestibular  symptom
mprovement  were  the  same  that  showed  no  improvement
or  the  symptom  of  headache.
Improvement  without  statistical  signiﬁcance  was
bserved  for  amitriptyline  50  mg  and  topiramate  200  mg;
lthough  smaller  doses  have  shown  a  signiﬁcant  improve-
ent,  that  must  be  due  to  the  fact  that  these  doses  were
sed  precisely  in  patients  who  did  not  respond  to  lower
oses,  that  is,  these  were  patients  with  refractory  symp-
oms,  despite  the  small  sample  size.  As  for  nortriptyline
0  mg;  valproate  500--1000  mg,  and  venlafaxine75  mg,  the
ow  number  of  patients  in  the  sample  may  have  been
esponsible  for  the  nonsigniﬁcant  improvement.  Finally,
ropranolol  seems  to  require  a  higher  dose  (80  mg/day)  to
how  improvement.
The  improvement  in  VAS  values  was  similar  among  theive  result,  as  all  drugs  led  to  an  improvement  subjectively
erceived  by  the  patient,  both  for  the  headache  symptom
nd  the  VS.  It  remains,  however,  difﬁcult  to  choose  the  best
VAS  among  the  three  treatment  regimens  used:  a  medication,
iation  of  two  drugs.
Mean  n  p
−4.53  41 0.174
−3.50  15
−2.50  7
−4.10  41 0.093
−2.21  15
−4.67  7
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Prophylactic  treatment  of  vestibular  migraine  
option  for  different  patients  with  VM  and  the  choice  is  made
according  to  possible  drug  contraindications  or  interactions
with  other  medications  that  patients  are  already  using,  try-
ing  to  optimize  patient  drug  therapy.
According  to  a  study  by  Bikhasi  et  al.,18 the  temporal
association  between  dizziness  and  migraine  did  not  inﬂu-
ence  the  efﬁciency  of  prophylactic  treatment.  In  this  study,
however,  a  statistically  signiﬁcant  association  between  dura-
tion  of  dizziness  and  therapeutic  response  for  dizziness  was
observed  (p  =  0.037).  The  duration  of  dizziness  also  showed
a  tendency  toward  a  negative  association  for  therapeutic
response  for  headache  (p  =  0.056).  This  shows  that  the  longer
the  duration  of  VS  experienced  by  the  patient,  the  bet-
ter  the  therapeutic  response  provided  by  prophylactic  drug
therapy.  Speciﬁc  studies  on  this  topic  are  needed  to  bet-
ter  answer  the  question  ‘‘Does  the  duration  of  vestibular
symptoms  inﬂuence  the  effectiveness  of  drug  prophylaxis?’’
The  choice  of  prophylactic  drug  is  based  on  the  patient’s
proﬁle  or  comorbidities  (antidepressants  for  patients  diag-
nosed  with  anxiety,  for  instance),  with  no  particular
advantage  of  one  group  of  drugs  over  the  others.11--13,17 In  the
current  sample,  the  group  of  hypertensive  patients  who  used
beta-blockers  as  prophylaxis  for  VM  and  the  group  of  anx-
ious/depressed  patients  who  used  antidepressants  did  not
show  any  statistically  signiﬁcant  advantage  with  the  use  of
these  drug  groups  compared  to  those  who  used  other  drugs.
This  fact  does  not  invalidate  the  current  recommendations
for  the  choice  of  prophylactic  drugs;  however,  it  raises  the
suspicion  (given  the  small  sample  size)  that  there  is  no  par-
ticular  advantage  in  improving  VM  symptoms.  Naturally,  in
the  context  of  rational  drug  use,  it  is  more  appropriate  to  use
a  single  drug  that  is  effective  for  two  patient  comorbidities
than  the  use  of  one  drug  for  each  disease.
Although  the  group  of  patients  with  substitution  drug  and
association  of  drugs  to  the  original  regimen  was  small,  that
prevented  a  more  detailed  study,  the  absence  of  statistical
difference  among  the  groups  of  patients  who  required  the
substitution  of  the  prophylactic  drug  supports  the  current
recommendations  that  there  is  no  group  of  drugs  better  than
the  other,  in  this  case,  even  when  two  drugs  were  used  in
combination.
Conclusions
The  prophylactic  medications  used  to  treat  VM  seem  to
improve  the  symptoms  of  this  disease.  There  is  no  group  of
prophylactic  drugs  exhibiting  better  results  than  others.  The
longer  the  duration  of  VS  experienced  by  the  patient,  the
better  is  the  therapeutic  response  to  the  prophylactic  drugs
used.  There  is  no  further  advantage,  in  addition  to  drug  ther-
apy  optimization,  related  to  the  reduction  in  headaches  and
1
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S  when  using  antidepressants  in  patients  with  a  diagnosis  of
epression  or  antihypertensive  medications  in  patients  with
AH.
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